US OptionsDetailed Quotes
BCLI241115P4000
- 0.00
- 0.000.00%
15min DelayClose Nov 15 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover0.00%IV-230.58%PremiumNov 15, 2024Expiry Date2.79Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Brainstorm Cell Therapeutics Stock Discussion
PR Newswire· 3 mins ago
Memorandum of Understanding has been signed
NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly o...
28/10/2024 - 18:00
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenera...
5 MINUTES AGO, 6:00 AM EDT
VIA PR NEWSWIRE
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
No comment yet